DOCSLIB.ORG

The Inhibitors of Apoptosis (Iaps) and Their Emerging Role in Cancer

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Inhibitors of Apoptosis (Iaps) and Their Emerging Role in Cancer Oncogene (1998) 17, 3247 ± 3259 ã 1998 Stockton Press All rights reserved 0950 ± 9232/98 $12.00 http://www.stockton-press.co.uk/onc The inhibitors of apoptosis (IAPs) and their emerging role in cancer Eric C LaCasse1, Stephen Baird1,2,3, Robert G Korneluk1,2,3 and Alex E MacKenzie*,1,2,3 1Apoptogen Inc, Suite R306, CHEO Research Institute, 401 Smyth Road, Ottawa, Ontario, Canada, K1H 8L1; 2Department of Pediatrics, University of Ottawa, Ontario, Canada and 3The Solange Gauthier Karsh Molecular Genetics Laboratory, Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada, K1H 8L1 The inhibitor of apoptosis protein family has been baculovirus, Autographa californica nuclear polyhedro- characterized over the past 5 years, initially in sis virus (AcMNPV) results in an unconstrained host baculovirus and more recently in metazoans. The IAPs lepidopteran SF-21 cell apoptosis. (The natural host are a widely expressed gene family of apoptotic cell apoptotic response to viral infection is usually inhibitors from both phylogenic and physiologic points eectively suppressed by the infecting baculovirus). of view. The diversity of triggers against which the IAPs Employing this assay, the CpGV and OpMNPV suppress apoptosis is greater than that observed for any genomes were screened for loci which would suppress other family of apoptotic inhibitors including the bcl-2 this cell death, resulting in the identi®cation of family. The central mechanisms of IAP apoptotic founding members of a new class of anti-apoptotic suppression appear to be through direct caspase and genes encoding Cp-IAP and Op-IAP, two proteins pro-caspase inhibition (primarily caspase 3 and 7) and which share both homology and the ability to block modulation of and by the transcription factor NF-kB. apoptosis by a wide number of apoptotic triggers Although evidence for a direct oncogenic role for the (Tables 1, 2 and 5). IAPs has yet to be delineated, a number of lines of evidence point towards this class of protein playing a role BIR and RING Zn ®nger domains in oncogenesis. The strongest evidence for IAP involve- ment in cancer is seen in the IAP called survivin. There exists in the baculoviral IAPs two de®ning Although not observed in adult dierentiated tissue, motifs. The ®rst of these is the BIR (for Baculoviral survivin is present in most transformed cell lines and Inhibitor of apoptosis Repeat) domain; a pair of these cancers tested to date. Survivin has been shown to inhibit comprise the amino terminal half of the viral IAPs. caspase directly and apoptosis in general, moreover The 80 amino acid BIR domain contains a possible survivin protein levels correlate inversely with 5 year serine/threonine phosphorylation site (RX2ST/F) fol- survival rates in colorectal cancer. Recent data has also lowed 17 residues downstream by an invariant glycine implicated survivin in cell cycle control. The second line and then DX3CX2C and HX6C consensus sequences of evidence for IAP involvement in cancer comes from (Figure 1). These latter arrays are also likely metal their emerging role as mediators and regulators of the coordination sites although this remains to be formally anti-apoptotic activity of v-Rel and NF-kB transcription documented; the physical structure of the BIR has not factor families. The IAPs have been shown to be induced yet been documented but is clearly a priority. The by NF-kB or v-Rel in multiple cell lines and conversely, importance of the non-conserved residues in the BIR HIAP1 and HIAP2 have been shown to activate NF-kB domain is re¯ected in the fact that the Ac-IAP found in possibly forming a positive feed-back loop. Overall a a third AcMNPV baculovirus, although containing the picture consistent with an IAP role in tumour progres- conserved BIR residues, is inactive with regard to sion rather than tumour initiation is emerging making apoptotic inhibition (Birnbaum et al., 1994). the IAPs an attractive therapeutic target. The second de®ning motif found in the baculoviral IAPs is the COOH terminus RING Zn ®nger (for Keywords: inhibitor of apoptosis; IAP; programmed Really Interesting New Gene, Freemont et al., 1991) cell death; BIR; RING ®nger; CARD; NAIP; survivin; containing a CX2 CXNCXHX2-3CX2 CXMCX2 C motif NF-kB; caspase (metal coordinating sites underlined, Figure 2). NMR based structural analysis has revealed the RING ®nger to assume a spherical cross brace structure with two Zn coordination sites identi®ed; one comprised of the ®rst Part A. The IAP family and third cluster of metal binding residues and the second coordination de®ned by the second and fourth The ®rst Inhibitor of Apoptosis (IAP) proteins were metal binding residue clusters (Barlow et al., 1994). identi®ed in 1993 and 1994 in the baculoviruses Cydia The RING Zn ®nger has been seen in nearly 100 pomonella granulosis virus (CpGV) and Orgyia proteins, is usually localized at the amino terminus of a pseudotsugata nuclear polyhedrosis virus (OpMNPV) protein and has been shown to be involved in DNA by the laboratory of Lois Miller (Crook et al., 1993; and protein interactions (Borden and Freemont, 1996). Birnbaum et al., 1994). The Miller lab utilized an assay The lack of conservation in the non-cys/his residues in which infection by a mutant strain of a third between various RING ®ngers is in keeping with the diverse functions postulated for these domains. The presence of the RING Zn ®nger appears to be critical to the baculoviral IAP anti-apoptotic function while it is dispensable for some (but not all) cellular IAP *Correspondence: AE MacKenzie apoptotic inhibition (Table 5). IAPs and cancer EC LaCasse et al 3248 Table 1 The IAP and BIR* family members (from 1993 ± 1998) Viral IAPs Baculovirus: CpIAP, OpIAP/OpIAP3, AcIAP*, OpBIRP2*, BusuIAP*, EpIAP* Other: ASFV IAP*/ORF 4CL and ORF A224L, CiVIAP* Nematode CeBIR2*, CeBIR1* Yeast SpBIR1*, ScBIR2* Drosophila IAPs 1 DIAP1/Thread Protein 2 DIAP/DIAP2/dILP/DIHA Vertebrate IAPs Human Murine Rat Porcine Chicken 1 NAIP mNAIP**/NAIP-rs rNAIP (partial) (6 genomic copies) 2 HIAPI/cIAP2/MIHC/hITA MIAP1 RIAP1 PIAP ITA/ch-IAP1 3 HIAP2/cIAP1/MIHB MIAP2/mcIAP1/API2 RIAP2/rIAP1 4 XIAP/hILP MIAP3/MIHA/mXIAP/API3 RIAP3 5 Survivin TIAP/msurvivin 6 BRUCE* **Murine NAIP homologs mNaip1 mNaip2 Naip-rs6 mNaip3 Naip-rs5 mNaip4 mNaip5 Naip-rs3 mNaip6 Abbreviations: IAP, inhibitor of apoptosis; BIR, baculoviral IAP repeat. *Contains a BIR domain, however, it has no proven anti-apoptotic function. CpIAP, Cydia pomonella Granulosis Virus IAP (L05494, U53466, P41436) Crook et al., 1993; OpIAP/OpIAP3, Orgyia pseudotsugata Nuclear Polyhedrosis Virus IAP (L 22564, P41437, U75930) Birnbaum et al., 1994; AcIAP, Autographa californica Nuclear Polyhedrosis Virus IAP (M96361) Clem and Miller, 1994; OpBIRP2, Orgyia pseudotsugata Nuclear Polyhedrosis virus BIR-containing protein 2 (U75930) Uren et al., 1998; BusuIAP, Buzura suppressaria Nuclear Polyhedrosis Virus IAP (AF045936), Hu et al., 1998; EpIAP, Epiphyas postvittana Nuclear Polyhedrosis Virus IAP (AF037358); ASFV IAP, African Swine Fever Virus IAP, ORF 4CL (U18466) Neilan et al., 1997 and ORF A234L Chacon et al., 1995; CiVIAP, Chilo iridescent Virus IAP (M81387, AF003534) Uren et al., 1998; CeBIR1, C. elegans BIR containing protein (Z77654) Uren et al., 1998; SpBIR1, S. pombe BIR containing protein 1 (AL 031323, 3451317) Uren et al., 1998; CeBIR2, C. elegans BIR containing protein 2, (U85911) Uren et al., 1998; ScBIR2, C. cerevisiae BIR containing protein 2 (L47993, 101 9708) Uren et al., 1998; DIAP1 Drosophila IAP 1 (L 49440) Hay et al., 1995; DIAP, Drosophila IAP (U45881, M96581) Liston et al., 1996; DIAP2, Drosophila IAP2 (L49441) Hay et al., 1995; dILP, Drosophila IAP-like protein (U32373) Duckett et al., 1996; DIHA, Drosophila IAP homolog A (U38809) Uren et al., 1996; NAIP, neuronal apoptosis inhibitory protein (U19251, U80017) Roy et al., 1995; Chen et al., 1998; mNAIP1-6, mouse NAIP-1 through 6 (AF007769) Yaraghi et al., 1998; NAIP-rs 1 through 6, NAIP related sequence 1 (U66324), 2 (U66325), 3 (U66326), 4 (U66327), 5 (U66328), 6 (U66329) Scharf et al., 1996; rNAIP, Rat NAIP (partial cDNA) Korneluk et al., (unpublished); HIAP1, human IAP1 (U45878) Liston et al., 1996; cIAP2, cellular IAP2 (L49432) Rothe et al., 1995; MIHC, mammalian IAP homolog C (U37546) Uren et al., 1996; hITA, human inhibitor of T-cell apoptosis, Nicholl et al., 1996; MIAP1, mouse IAP1 (U88908) Liston et al., 1997; RIAP1, rat IAP1 Holcik et al., (unpublished); PIAP, porcine IAP (U79142) Stehlik et al., 1998b; ITA, inhibitor of T-cell apoptosis (U27466) Digby et al., 1996; ch-IAP1, chicken IAP1 (AF008592) You et al., 1997; HIAP2, human IAP2 (U45879) Liston et al., 1996; cIAP1, cellular IAP1 (L49431) Rothe et al., 1995; MIHB, mammalian IAP homolog B (U37547) Uren et al., 1996; MIAP2, mouse IAP2 (U88909) Liston et al., 1997; mcIAP1, mouse cellular IAP1 (L49433) Rothe et al., 1995; API2, mouse apoptosis inhibitor 2; RIAP2, rat IAP2 Holcik et al., (unpublished); rIAP1, rat IAP1 (3445577, AF081503) Bradley, Lareu and Dharmarajan (unpublished); XIAP, X-linked IAP (U45880) Liston et al., 1996; hILP, human IAP-like protein (U32974) Duckett et al., 1996; MIAP3, mouse IAP3 (U88990) Farahani et al., 1997; MIHA, mammalian IAP homolog A (U36842) Uren et al., 1996; mXIAP, mouse XIAP; API3, mouse apoptosis inhibitor 3; RIAP3, rat IAP3, Holcik et al., (unpublished); survivin (U75285) Ambrosini et al., 1997; TIAP, thymus/testis-speci®c IAP (murine survivin homolog) (AB013819) Kobayashi et al., (unpublished); msurvivin, mouse survivin, Gibson, Holcik and Korneluk (unpublished); BRUCE, BIR-Repeat containing ubiquitin conjugating enzyme (Y17267) Hauser et al., 1998. NB accession numbers refer to either gene, genome or protein sequence. Table 2 Classi®cation according to homology domain Non-viral IAPs Category Examples The initial baculoviral IAP discovery was followed in 1 BIR survivin, BRUCE*, ASFV IAP*, 1995 by the identi®cation of a series of metazoan IAPs, CeBIR2* the ®rst of these being the NAIP gene.
Load more

Recommended publications
  • Induced Apoptosis
    APOPTOSIS INDUCTION AND IMMUNOTHERAPY-HOW TO IMPROVE RESULTS OF IMMUNOTHERAPY C/ Professor Peter Hersey University of Newcastle NSW Australia IMMUNOTHERAPY DEPENDS ON INDUCTION OF APOPTOSIS! • IF WE UNDERSTAND THE RESISTANCE MECHANISMS AGAINST APOPTOSIS WE CAN TARGET THESE AND IMPROVE THE RESULTS OF IMMUNOTHERAPY CELL KILLING MECHANISMS USED BY LYMPHOCYTES DEPEND ON INDUCTION OF APOPTOSIS 1. Granzyme – Perforin Mediated Killing CD8 CTL (CD4 CTL) NK Cells and ADCC 2.Death Ligand Mediated Killing TRAIL, FasL, TNF CD4 T Cells Monocytes, Dendritic Cells CURRENTCURRENT CONCEPTSCONCEPTS ININ APOPTOSISAPOPTOSIS TRAIL, Granz B P53.-NOXA, BID CYTOSKELETON PUMA,BAD,BID BIM,BMF Bcl-2,Bcl-xL.Mcl-1 ER Stress, Bik,PUMA,Noxa Bax,Bak Mitochondria Smac,Omi Cyto c, Casp 9 IAPs Classical Pathway Effector Caspases 3,7 MITOCHONDRIAL PATHWAYS TO APOPTOSIS ARE REGULATED BY BCL-2 FAMILY PROTEINS • Pro-apoptotic BH3 only damage sensor proteins (Bid, Bik,Bim, Bmf, Noxa,Puma,Bad,Hrk) • Pro-apoptotic multidomain proteins: BAX, BAK • Anti-apoptotic proteins: BCL-2, BCL-Xl, MCL-1, Bcl-W,A1 WE ALREADY HAVE AGENTS THAT TARGET THE ANTI APOPTOTIC PROTEINS! Targetting Anti Apoptotic Proteins • Genasense against Bcl-2. • Inhibition of production of the IAP protein Survivin YM155 (Astellas Pharm • BH3 mimics that bind Bcl-2 proteins(Abbott ABT-737) Targetting Anti-Apoptotic Proteins • AT-101 (Gossypol) Oral inhibitor of Bcl-2 Bcl- XL,Mcl-1 . Ascenta Therapeutics • TW37- Small mw mimic of Bim that inhibits Bcl-2, Bcl-XL,Mcl-1. Univ Michigan • Obatoclax (GX015-070) Small mw BH3 mimic . Inhibits Bcl-2,Bcl-XL,Mcl-1. (Gemin X) TRAIL INDUCED KILLING REQUIRES DEATH RECEPTORS! TRAIL Induces Apoptosis in the Majority of Melanoma Cell Lines 100 90 80 70 60 50 40 30 % Apoptotic Cells % Apoptotic 20 10 0 1 2 3 4 5 6 7 8 9 101112131415161718192021222324252627282930 Melanoma Cell Lines TRAIL-R1 & R2 Expression Correlates with Degree of Apoptosis L I A 120 120 R T 100 100 y b 80 80 d e 60 60 c u d 40 40 n I s 20 20 si o 0 0 t p -20 o -20 p A -10 10 30 50 70 90 -10 10 30 50 70 90 % TRAIL-R1 TRAIL-R2 Zhang et al.
    [Show full text]
  • Inhibitor of Apoptosis Proteins As Therapeutic Targets in Multiple Myeloma
    Leukemia (2014) 28, 1519–1528 & 2014 Macmillan Publishers Limited All rights reserved 0887-6924/14 www.nature.com/leu ORIGINAL ARTICLE Inhibitor of apoptosis proteins as therapeutic targets in multiple myeloma V Ramakrishnan1, U Painuly1,2, T Kimlinger1, J Haug1, SV Rajkumar1 and S Kumar1 The inhibitor of apoptosis (IAP) proteins have a critical role in the control of apoptotic machinery, and has been explored as a therapeutic target. Here, we have examined the functional importance of IAPs in multiple myeloma (MM) by using a Smac (second mitochondria-derived activator of caspases)-mimetic LCL161. We observed that LCL161 was able to potently induce apoptosis in some MM cell lines but not in others. Examining the levels of X-linked inhibitor of apoptosis protein (XIAP), cellular inhibitor of apoptosis protein 1 (cIAP1) and cellular inhibitor of apoptosis protein 2 (cIAP2) post LCL161 treatment indicated clear downregulation of both XIAP activity and cIAP1 levels in both the sensitive and less sensitive (resistant) cell lines. cIAP2, however, was not downregulated in the cell line resistant to the drug. Small interfering RNA-mediated silencing of cIAP2 significantly enhanced the effect of LCL161, indicating the importance of downregulation of all IAPs simultaneously for induction of apoptosis in MM cells. LCL161 induced marked up regulation of the Jak2/Stat3 pathway in the resistant MM cell lines. Combining LCL161 with a Jak2-specific inhibitor resulted in synergistic cell death in MM cell lines and patient cells. In addition, combining LCL161 with death- inducing ligands clearly showed that LCL161 sensitized MM cells to both Fas-ligand and TRAIL.
    [Show full text]
  • 505.Full.Pdf
    Pseudomonas aeruginosa Delays Kupffer Cell Death via Stabilization of the X-Chromosome-Linked Inhibitor of Apoptosis Protein This information is current as of September 26, 2021. Alix Ashare, Martha M. Monick, Amanda B. Nymon, John M. Morrison, Matthew Noble, Linda S. Powers, Timur O. Yarovinsky, Timothy L. Yahr and Gary W. Hunninghake J Immunol 2007; 179:505-513; ; doi: 10.4049/jimmunol.179.1.505 Downloaded from http://www.jimmunol.org/content/179/1/505 References This article cites 44 articles, 21 of which you can access for free at: http://www.jimmunol.org/ http://www.jimmunol.org/content/179/1/505.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists by guest on September 26, 2021 • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2007 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Pseudomonas aeruginosa Delays Kupffer Cell Death via Stabilization of the X-Chromosome-Linked Inhibitor of Apoptosis Protein1 Alix Ashare,2* Martha M.
    [Show full text]
  • Blockade of BCL-2 Proteins Efficiently Induces Apoptosis in Progenitor
    Leukemia (2016) 30, 112–123 © 2016 Macmillan Publishers Limited All rights reserved 0887-6924/16 www.nature.com/leu ORIGINAL ARTICLE Blockade of BCL-2 proteins efficiently induces apoptosis in progenitor cells of high-risk myelodysplastic syndromes patients S Jilg1, V Reidel1, C Müller-Thomas1, J König1, J Schauwecker2, U Höckendorf1, C Huberle1, O Gorka3, B Schmidt4, R Burgkart2, J Ruland3, H-J Kolb1, C Peschel1, RAJ Oostendorp1, KS Götze1 and PJ Jost1 Deregulated apoptosis is an identifying feature of myelodysplastic syndromes (MDS). Whereas apoptosis is increased in the bone marrow (BM) of low-risk MDS patients, progression to high-risk MDS correlates with an acquired resistance to apoptosis and an aberrant expression of BCL-2 proteins. To overcome the acquired apoptotic resistance in high-risk MDS, we investigated the induction of apoptosis by inhibition of pro-survival BCL-2 proteins using the BCL-2/-XL/-W inhibitor ABT-737 or the BCL-2-selective inhibitor ABT-199. We characterized a cohort of 124 primary human BM samples from MDS/secondary acute myeloid leukemia (sAML) patients and 57 healthy, age-matched controls. Inhibition of anti-apoptotic BCL-2 proteins was specifically toxic for BM cells from high-risk MDS and sAML patients, whereas low-risk MDS or healthy controls remained unaffected. Notably, ABT-737 or ABT-199 treatment was capable of targeting the MDS stem/progenitor compartment in high-risk MDS/sAML samples as shown by the reduction in CD34+ cells and the decreased colony-forming capacity. Elevated expression of MCL-1 conveyed resistance against both compounds. Protection by stromal cells only partially inhibited induction of apoptosis.
    [Show full text]
  • Apoptosis Ligand-Induced Enhanced Resistance to Fas/Fas
    Theileria parva-Transformed T Cells Show Enhanced Resistance to Fas/Fas Ligand-Induced Apoptosis This information is current as Peter Küenzi, Pascal Schneider and Dirk A. E. Dobbelaere of October 2, 2021. J Immunol 2003; 171:1224-1231; ; doi: 10.4049/jimmunol.171.3.1224 http://www.jimmunol.org/content/171/3/1224 Downloaded from References This article cites 69 articles, 29 of which you can access for free at: http://www.jimmunol.org/content/171/3/1224.full#ref-list-1 Why The JI? Submit online. http://www.jimmunol.org/ • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average by guest on October 2, 2021 Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2003 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Theileria parva-Transformed T Cells Show Enhanced Resistance to Fas/Fas Ligand-Induced Apoptosis1 Peter Ku¨enzi,2* Pascal Schneider,† and Dirk A. E. Dobbelaere3* Lymphocyte homeostasis is regulated by mechanisms that control lymphocyte proliferation and apoptosis. Activation-induced cell death is mediated by the expression of death ligands and receptors, which, when triggered, activate an apoptotic cascade.
    [Show full text]
  • Regulation of Caspase-9 by Natural and Synthetic Inhibitors Kristen L
    University of Massachusetts Amherst ScholarWorks@UMass Amherst Open Access Dissertations 5-2012 Regulation of Caspase-9 by Natural and Synthetic Inhibitors Kristen L. Huber University of Massachusetts Amherst, [email protected] Follow this and additional works at: https://scholarworks.umass.edu/open_access_dissertations Part of the Chemistry Commons Recommended Citation Huber, Kristen L., "Regulation of Caspase-9 by Natural and Synthetic Inhibitors" (2012). Open Access Dissertations. 554. https://doi.org/10.7275/jr9n-gz79 https://scholarworks.umass.edu/open_access_dissertations/554 This Open Access Dissertation is brought to you for free and open access by ScholarWorks@UMass Amherst. It has been accepted for inclusion in Open Access Dissertations by an authorized administrator of ScholarWorks@UMass Amherst. For more information, please contact [email protected]. REGULATION OF CASPASE-9 BY NATURAL AND SYNTHETIC INHIBITORS A Dissertation Presented by KRISTEN L. HUBER Submitted to the Graduate School of the University of Massachusetts Amherst in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY MAY 2012 Chemistry © Copyright by Kristen L. Huber 2012 All Rights Reserved REGULATION OF CASPASE-9 BY NATURAL AND SYNTHETIC INHIBITORS A Dissertation Presented by KRISTEN L. HUBER Approved as to style and content by: _________________________________________ Jeanne A. Hardy, Chair _________________________________________ Lila M. Gierasch, Member _________________________________________ Robert M. Weis,
    [Show full text]
  • The Immuno-Modulatory Effects of Inhibitor of Apoptosis Protein
    cells Review The Immuno-Modulatory Effects of Inhibitor of Apoptosis Protein Antagonists in Cancer Immunotherapy Jessica Michie 1,2, Conor J. Kearney 1,2, Edwin D. Hawkins 1,3, John Silke 3,4 and Jane Oliaro 1,2,5,* 1 Peter MacCallum Cancer Centre, Melbourne, VI 3000, Australia; [email protected] (J.M.); [email protected] (C.J.K.); [email protected] (E.D.H.) 2 Sir Peter MacCallum Department of Oncology, The University of Melbourne, VI 3010, Australia 3 The Walter and Eliza Hall Institute of Medical Research, VI 3010, Australia; [email protected] 4 Department of Medical Biology, University of Melbourne, Parkville, VI 3010, Australia 5 Department of Immunology, Monash University, Melbourne, VI 3004, Australia * Correspondence: [email protected]; Tel.: +61-3-8559-7094 Received: 29 November 2019; Accepted: 11 January 2020; Published: 14 January 2020 Abstract: One of the hallmarks of cancer cells is their ability to evade cell death via apoptosis. The inhibitor of apoptosis proteins (IAPs) are a family of proteins that act to promote cell survival. For this reason, upregulation of IAPs is associated with a number of cancer types as a mechanism of resistance to cell death and chemotherapy. As such, IAPs are considered a promising therapeutic target for cancer treatment, based on the role of IAPs in resistance to apoptosis, tumour progression and poor patient prognosis. The mitochondrial protein smac (second mitochondrial activator of caspases), is an endogenous inhibitor of IAPs, and several small molecule mimetics of smac (smac-mimetics) have been developed in order to antagonise IAPs in cancer cells and restore sensitivity to apoptotic stimuli.
    [Show full text]
  • Potential Biomarkers for Treatment Response to the BCL-2 Inhibitor Venetoclax: State of the Art and Future Directions
    cancers Review Potential Biomarkers for Treatment Response to the BCL-2 Inhibitor Venetoclax: State of the Art and Future Directions Haneen T. Salah 1 , Courtney D. DiNardo 2 , Marina Konopleva 2 and Joseph D. Khoury 3,* 1 College of Medicine, Alfaisal University, Riyadh 11533, Saudi Arabia; [email protected] 2 Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; [email protected] (C.D.D.); [email protected] (M.K.) 3 Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA * Correspondence: [email protected] Simple Summary: Apoptosis dysergulation is vital to oncogenesis. Efforts to mitigate this cancer hallmark have been ongoing for decades, focused mostly on inhibiting BCL-2, a key anti-apoptosis effector. The approval of venetoclax, a selective BCL-2 inhibitor, for clinical use has been a turning point in the field of oncology. While resulting in impressive improvement in objective outcomes, particularly for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and acute myeloid leukemia, the use of venetoclax has exposed a variety of resistance mechanisms to BCL-2 inhibition. As the field continues to move forward, improved understanding of such mechanisms and the potential biomarkers that could be harnessed to optimize patient selection for therapies that include venetoclax and next-generation BCL-2 inhibitors are gaining increased importance. Abstract: Intrinsic apoptotic pathway dysregulation plays an essential role in all cancers, particularly hematologic malignancies. This role has led to the development of multiple therapeutic agents Citation: Salah, H.T.; DiNardo, C.D.; targeting this pathway.
    [Show full text]
  • The Pseudo-Caspase FLIP(L) Regulates Cell Fate Following P53 Activation
    The pseudo-caspase FLIP(L) regulates cell fate following p53 activation Andrea Leesa,1, Alexander J. McIntyrea,1, Nyree T. Crawforda, Fiammetta Falconea, Christopher McCanna, Caitriona Holohana, Gerard P. Quinna, Jamie Z. Robertsa, Tamas Sesslera, Peter F. Gallaghera, Gemma M. A. Gregga, Katherine McAllistera, Kirsty M. McLaughlina, Wendy L. Allena, Laurence J. Eganb, Aideen E. Ryanb,c, Melissa J. Labonte-Wilsona, Philip D. Dunnea, Mark Wappetta, Vicky M. Coylea, Patrick G. Johnstona, Emma M. Kerra, Daniel B. Longleya,2,3, and Simon S. McDadea,2,3 aPatrick G Johnston Centre for Cancer Research, Queen’s University Belfast, Belfast, Northern Ireland BT9 7BL, United Kingdom; bDiscipline of Pharmacology & Therapeutics, Lambe Institute for Translational Research, School of Medicine, College of Medicine, Nursing and Health Sciences, National University of Ireland Galway, Galway, Ireland; and cRegenerative Medicine Institute, College of Medicine, Nursing and Health Sciences, National University of Ireland Galway, Galway, Ireland Edited by Karen H. Vousden, Francis Crick Institute, London, United Kingdom, and approved June 8, 2020 (received for review February 12, 2020) p53 is the most frequently mutated, well-studied tumor-suppressor switch from cell-cycle arrest to cell death induction remain gene, yet the molecular basis of the switch from p53-induced cell- poorly understood, although p53-mediated transcriptional up- cycle arrest to apoptosis remains poorly understood. Using a combi- regulation of PUMA has been suggested to be crucial in a nation of transcriptomics and functional genomics, we unexpectedly number of studies (10, 11). identified a nodal role for the caspase-8 paralog and only human Despite p53/TP53 being the most frequently mutated gene in pseudo-caspase, FLIP(L), in regulating this switch.
    [Show full text]
  • Therapeutic Small Molecules Target Inhibitor of Apoptosis Proteins In
    Published OnlineFirst December 30, 2016; DOI: 10.1158/1078-0432.CCR-16-2172 Review Clinical Cancer Research Therapeutic Small Molecules Target Inhibitor of Apoptosis Proteins in Cancers with Deregulation of Extrinsic and Intrinsic Cell Death Pathways Adeeb Derakhshan, Zhong Chen, and Carter Van Waes Abstract TheCancerGenomeAtlas(TCGA)hasunveiledgenomic the results of targeting IAPs in preclinical models of HNSCC deregulation of various components of the extrinsic and intrin- using SMAC mimetics. Synergistic activity of SMAC mimetics sic apoptotic pathways in different types of cancers. Such together with death agonists TNFa or TRAIL occurred in vitro, alterations are particularly common in head and neck squa- whereas their antitumor effects were augmented when com- mous cell carcinomas (HNSCC), which frequently display bined with radiation and chemotherapeutic agents that induce amplification and overexpression of the Fas-associated via TNFa in vivo. In addition, clinical trials testing SMAC mimetics death domain (FADD) and inhibitor of apoptosis proteins as single agents or together with chemo- or radiation therapies (IAP) that complex with members of the TNF receptor family. in patients with HNSCC and solid tumors are summarized. Second mitochondria-derived activator of caspases (SMAC) As we achieve a deeper understanding of the genomic altera- mimetics, modeled after the endogenous IAP antagonist tions and molecular mechanisms underlying deregulated SMAC, and IAP inhibitors represent important classes of novel death and survival pathways in different cancers, the role small molecules currently in phase I/II clinical trials. Here we of SMAC mimetics and IAP inhibitors in cancer treatment will review the physiologic roles of IAPs, FADD, and other com- be elucidated.
    [Show full text]
  • Caspase-3 and Inhibitor of Apoptosis Protein(S) Interactionsprovided Byin Elsevier - Publisher Connector Saccharomyces Cerevisiae and Mammalian Cells
    FEBS 24075 FEBS Letters 481 (2000) 13^18 View metadata, citation and similar papers at core.ac.uk brought to you by CORE Caspase-3 and inhibitor of apoptosis protein(s) interactionsprovided byin Elsevier - Publisher Connector Saccharomyces cerevisiae and mammalian cells Michael E. Wrighta, David K. Hanb, David M. Hockenberya;* aMolecular and Cellular Biology Program, Divisions of Clinical Research and Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA 98109-1024, USA bDepartment of Molecular Biotechnology, University of Washington, Seattle, WA, USA Received 7 August 2000; accepted 11 August 2000 Edited by Vladimir Skulachev optosis proteins (IAPs) [3,4]. The IAPs were originally Abstract Using a heterologous yeast expression assay, we show that inhibitor of apoptosis proteins (IAPs) suppress caspase-3- described by an activity that prevents apoptotic cell deaths mediated cytotoxicity in the order of XIAP s c-IAP2 s c- caused by multiple triggers in Drosophila, Caenorhabditis ele- IAP1 s survivin. The same ordering of IAP activities was gans and mammalian cells [5,6]. Subsequently, several labs demonstrated in mammalian cells expressing an auto-activating demonstrated by in vitro assays that IAPs function as direct caspase-3. The relative anti-apoptotic activities of each IAP inhibitors for speci¢c caspases [7^9]. Speci¢cally, three mam- depended on the particular death stimulus. For IAP-expressing malian IAPs, c-IAP1, c-IAP2, and XIAP, are direct inhibitors cells treated with camptothecin, survival correlated with their of recombinant caspases-3, -7, and -9 [7^9]. This is generally intrinsic anti-caspase-3 activity. However, c-IAP1-transfected accepted to be the principal mechanism for the anti-apoptotic cells were disproportionately resistant to tumor necrosis factor- activity of the IAPs in various experimental settings [4].
    [Show full text]
  • Roles of Bid and XIAP
    Cell Death and Differentiation (2012) 19, 42–50 & 2012 Macmillan Publishers Limited All rights reserved 1350-9047/12 www.nature.com/cdd Review Fas death receptor signalling: roles of Bid and XIAP T Kaufmann*,1, A Strasser2,3 and PJ Jost4 Fas (also called CD95 or APO-1), a member of a subgroup of the tumour necrosis factor receptor superfamily that contain an intracellular death domain, can initiate apoptosis signalling and has a critical role in the regulation of the immune system. Fas-induced apoptosis requires recruitment and activation of the initiator caspase, caspase-8 (in humans also caspase-10), within the death-inducing signalling complex. In so-called type 1 cells, proteolytic activation of effector caspases (-3 and -7) by caspase-8 suffices for efficient apoptosis induction. In so-called type 2 cells, however, killing requires amplification of the caspase cascade. This can be achieved through caspase-8-mediated proteolytic activation of the pro-apoptotic Bcl-2 homology domain (BH)3-only protein BH3-interacting domain death agonist (Bid), which then causes mitochondrial outer membrane permeabilisation. This in turn leads to mitochondrial release of apoptogenic proteins, such as cytochrome c and, pertinent for Fas death receptor (DR)-induced apoptosis, Smac/DIABLO (second mitochondria-derived activator of caspase/direct IAP binding protein with low Pi), an antagonist of X-linked inhibitor of apoptosis (XIAP), which imposes a brake on effector caspases. In this review, written in honour of Juerg Tschopp who contributed so much to research on cell death and immunology, we discuss the functions of Bid and XIAP in the control of Fas DR-induced apoptosis signalling, and we speculate on how this knowledge could be exploited to develop novel regimes for treatment of cancer.
    [Show full text]